BioCentury
ARTICLE | Clinical News

Basilea preclinical data

April 28, 2014 7:00 AM UTC

In mouse xenograft models of chemo-sensitive and chemo-refractory breast cancer, IV BAL101553 produced significant antitumor activity vs. controls (p<0.05). Additionally, in a mouse xenograft model of trastuzumab-refractory breast cancer, BAL101553 in combination with trastuzumab led to significantly greater antitumor activity vs. trastuzumab alone (p<0.05) and significantly delayed tumor growth vs. controls (p=0.002). Data were presented at the American Association for Cancer Research meeting in San Diego. ...